Nyrada
Menu
NYR:
Market Cap*:
Price Delay ~20min
Home
About Us
Company Overview
Board of Directors
Management
Scientific Advisory Board
Corporate Governance
Our Science
Lead Drug Development
Cholesterol-Lowering Program
Brain Injury Program
Technical Glossary
Drug Development Pathway
Investors
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Corporate Announcements
Investor Presentations
Financial Reports
Share Price Information
Key Dates
Investors Glossary
Financial Reports
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
News & Insights
Presentations & Interviews
Media
Newsletters
Publications
Contact Us
Contact Us
Working at Nyrada
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Welcome
ASX Announcements
Brain Injury Program
Cholesterol-Lowering Program
Corporate Announcements
Investor Presentations
Financial Reports
Share Price Information
Key Dates
Investors Glossary
Financial Reports
Annual Reports
Analyst Reports
Annual General Meeting
Past Shareholder Meetings
ASX Announcements
Filter by Year:
2023
2022
2021
2020
24-Feb-2023
Nyrada Half Year Results FY2023
24-Feb-2023
Appendix 4D and Half Year Report to 31 December 2022
30-Jan-2023
Quarterly Activities Report and Appendix 4C
18-Jan-2023
Collaboration with Walter Reed and UNSW Extended to 2025
16-Jan-2023
Notification of cessation of securities - NYR
11-Jan-2023
Brain Injury Program Update
21-Nov-2022
Results of Meeting
21-Nov-2022
AGM Presentation by James Bonnar CEO
21-Nov-2022
Nyrada AGM 2022 Chairmans Address
18-Nov-2022
Nyrada Receives A$1.2M R&D Tax Incentive Rebate
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Next
